title: Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).
abstract: OBJECTIVE
  A 12-month multicenter, double-blind trial in which maintenance renal transplant patients were randomized to remain on mycophenolate mofetil (MMF) or convert to enteric-coated mycophenolate sodium (EC-MPS, myfortic) has demonstrated that conversion from MMF to EC-MPS is safe. Patients completing the study were invited to enter an open-label extension. Upon entry to the extension, patients who had received MMF during the randomized phase were converted to EC-MPS ("newly-exposed EC-MPS" group) and were monitored separately from those who had been randomized to EC-MPS ("long-term EC-MPS" group). The aim of the extension study was to collect long-term safety and efficacy data on EC-MPS, and to confirm the safety of conversion from MMF to EC-MPS in a larger patient population.
  
  
  METHODS
  All patients received EC-MPS 720 mg b.i.d. with cyclosporine microemulsion and corticosteroids per local practice. Data derived from the analysis of the first 24 months of the extension phase are presented.
  
  
  RESULTS
  Of the 297 patients who completed the core study, 260 (88%) entered the extension; 195 (75%) completed the 24-month extension visit. For on-treatment patients > 95% of the planned daily dose of EC-MPS was administered, and < 13% of patients in both groups had discontinued EC-MPS due to adverse events by 24 months. The overall incidence of adverse events during the extension phase, including infections and hematological abnormalities, was comparable to that seen in the core study, with a similar safety profile in the newly-exposed and long-term EC-MPS groups. There were 3 deaths during the first 24 months of the extension, and 2 graft failures in both the "newly-exposed" and "long-term" EC-MPS groups.
  
  
  CONCLUSIONS
  These data demonstrate that long-term use of EC-MPS is effective and has an acceptable tolerability profile in renal transplant patients, and confirm that conversion of maintenance renal transplant patients from MMF to EC-MPS is a safe therapeutic option.
authors.affiliation: Department of Nephrology, Campus Charité Mitte Charitè, Humboldt University, Berlin, Germany. klemens.budde@charite.de
authors.forename: K
authors.initials: K
authors.lastname: Budde
authors.forename: G
authors.initials: G
authors.lastname: Knoll
authors.forename: J
authors.initials: J
authors.lastname: Curtis
authors.forename: L
authors.initials: L
authors.lastname: Chan
authors.forename: E
authors.initials: E
authors.lastname: Pohanka
authors.forename: M
authors.initials: M
authors.lastname: Gentil
authors.forename: Y
authors.initials: Y
authors.lastname: Seifu
authors.forename: A C
authors.initials: AC
authors.lastname: Marrast
authors.forename: H H
authors.initials: HH
authors.lastname: Neumayer
mesh_terms: D000328:Adult; D016572:Cyclosporine / Q000008:administration & dosage; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D012449:Safety; D013608:Tablets, Enteric-Coated; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D013608:Tablets, Enteric-Coated; D016572:Cyclosporine; D009173:Mycophenolic Acid